The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
13 Dec 2022
Historique:
received: 07 09 2022
revised: 03 12 2022
accepted: 09 12 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

Hyperprogressive disease (HPD), an aggressive acceleration of tumor growth, was observed in a group of cancer patients treated with anti-PD1/PDL1 antibodies. The presence of a peculiar macrophage subset in the tumor microenvironment is reported to be a sort of "immunological prerequisite" for HPD development. These macrophages possess a unique phenotype that it is not clear how they acquire. We hypothesized that certain malignant cells may promote the induction of an "HPD-related" phenotype in macrophages. Bone-marrow-derived macrophages were exposed to the conditioned medium of five non-small cell lung cancer cell lines. Macrophage phenotype was analyzed by microarray gene expression profile and real-time PCR. We found that human NSCLC cell lines, reported as undergoing HPD-like tumor growth in immunodeficient mice, polarized macrophages towards a peculiar pro-inflammatory phenotype sharing both M1 and M2 features. Lipid-based factors contained in cancer cell-conditioned medium induced the over-expression of several pro-inflammatory cytokines and the activation of innate immune receptor signaling pathways. We also determined that tumor-derived Extracellular Vesicles represent the main components involved in the observed macrophage re-education program. The present study might represent the starting point for the future development of diagnostic tools to identify potential hyperprogressors.

Identifiants

pubmed: 36555441
pii: ijms232415802
doi: 10.3390/ijms232415802
pmc: PMC9779478
pii:
doi:

Substances chimiques

Culture Media, Conditioned 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Association for Cancer Research
ID : 20554

Références

MAbs. 2021 Jan-Dec;13(1):1954136
pubmed: 34313545
JTO Clin Res Rep. 2020 Feb 11;1(1):100001
pubmed: 34589908
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Eur J Pharm Biopharm. 2020 Jan;146:55-63
pubmed: 31805356
Cancers (Basel). 2021 Sep 20;13(18):
pubmed: 34572931
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207286
J Immunol Methods. 2020 Mar;478:112721
pubmed: 32033786
J Immunol Res. 2019 Nov 4;2019:1919082
pubmed: 31781673
PLoS One. 2016 Dec 29;11(12):e0168793
pubmed: 28033353
Cancer Immunol Res. 2021 Mar;9(3):309-323
pubmed: 33361087
Oncoimmunology. 2021 Feb 22;10(1):1887552
pubmed: 33680573
Shock. 2016 Aug;46(2):122-31
pubmed: 26954942
Int J Oncol. 2021 May;58(5):
pubmed: 33760183
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Mol Med. 2021 Sep 28;27(1):121
pubmed: 34583655
Biomark Res. 2022 Jan 27;10(1):5
pubmed: 35086565
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Front Cell Dev Biol. 2021 Oct 08;9:746432
pubmed: 34692700
Sci Rep. 2014 Jul 18;4:5750
pubmed: 25034888
Immunopharmacol Immunotoxicol. 1999 Aug;21(3):565-82
pubmed: 10466080
Cancer Res. 2016 Jun 1;76(11):3189-99
pubmed: 27197187
Hepatology. 2019 Jul;70(1):198-214
pubmed: 30810243
PLoS One. 2020 Jul 13;15(7):e0236038
pubmed: 32658933
J Mol Endocrinol. 2022 May 23;69(2):315-327
pubmed: 35604113
Biochim Biophys Acta. 2015 Jul;1852(7):1540-9
pubmed: 25912735
Sci Transl Med. 2022 Nov 23;14(672):eabq7019
pubmed: 36417489
Front Oncol. 2022 Feb 10;11:662723
pubmed: 35223446
J Exp Clin Cancer Res. 2020 Nov 9;39(1):236
pubmed: 33168050
Nat Genet. 2006 May;38(5):500-1
pubmed: 16642009
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Pharmacol Ther. 2017 Sep;177:81-95
pubmed: 28245991
Front Immunol. 2022 Jan 28;13:807050
pubmed: 35154124
J Thorac Oncol. 2020 Mar;15(3):360-370
pubmed: 31634668
Mol Ther. 2013 Feb;21(2):409-22
pubmed: 22929659
PLoS One. 2017 Jul 17;12(7):e0181125
pubmed: 28715437
Exp Hematol. 1999 Feb;27(2):337-44
pubmed: 10029173
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
J Clin Invest. 2015 Nov 2;125(11):4149-59
pubmed: 26436647
Cancers (Basel). 2020 May 23;12(5):
pubmed: 32456204
Cancers (Basel). 2019 Aug 27;11(9):
pubmed: 31461915
Nat Commun. 2021 Jan 28;12(1):647
pubmed: 33510144
J Thorac Oncol. 2022 Oct;17(10):1178-1191
pubmed: 35798240
Front Immunol. 2020 Apr 15;11:625
pubmed: 32351507
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
J Leukoc Biol. 2019 Aug;106(2):345-358
pubmed: 30576000
Cell Biosci. 2019 Jul 03;9:55
pubmed: 31304005
Front Immunol. 2018 Mar 12;9:444
pubmed: 29593717
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
Front Oncol. 2020 Feb 25;10:188
pubmed: 32161718
Oncol Ther. 2018 Dec;6(2):109-127
pubmed: 32700032
Int J Cancer. 2018 Oct 1;143(7):1741-1752
pubmed: 29667169
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359572
Front Immunol. 2019 Jul 31;10:1818
pubmed: 31417576
J Clin Invest. 2013 Aug;123(8):3363-72
pubmed: 23863624
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Front Cell Dev Biol. 2021 Sep 17;9:732192
pubmed: 34604233
J Clin Invest. 2005 Aug;115(8):2223-33
pubmed: 16025156
Br J Cancer. 2008 Jul 22;99(2):245-52
pubmed: 18594528
Cell Death Dis. 2022 Apr 20;13(4):382
pubmed: 35443741
Clin Cancer Res. 2016 Jan 15;22(2):436-47
pubmed: 26324743
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
BMC Med. 2022 May 13;20(1):187
pubmed: 35550592
Sci Signal. 2016 Jun 28;9(434):ra64
pubmed: 27353364
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Cancers (Basel). 2021 Aug 13;13(16):
pubmed: 34439233

Auteurs

Serena Indino (S)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Cristina Borzi (C)

Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Claudia Moscheni (C)

Dipartimento di Scienze Biomediche e Cliniche, Università degli Studi di Milano, Via G. B. Grassi, 74, L.I.T.A. Vialba, 20157 Milan, Italy.

Patrizia Sartori (P)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Loris De Cecco (L)

Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy.

Giancarla Bernardo (G)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Valentino Le Noci (V)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Francesca Arnaboldi (F)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Tiziana Triulzi (T)

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy.

Gabriella Sozzi (G)

Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Elda Tagliabue (E)

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy.

Lucia Sfondrini (L)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.
Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy.

Nicoletta Gagliano (N)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.

Massimo Moro (M)

Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Michele Sommariva (M)

Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milan, Italy.
Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH